Chitosan-based nanocomposites have demonstrated numerous physicochemical, biological, and functional properties making them well-suited for a range of biomedical applications, particularly in drug delivery. In this study, a chitosan–zinc oxide nanocomposite (CS–ZnO NCs) was developed as a carrier for ciprofloxacin loading. The nanocomposite (CS-ZnO) was synthesized via an in situ redox reaction and characterized using Dynamic Light Scattering (DLS), Scanning Electron Microscopy (SEM), Fourier Transform Infrared Spectroscopy (FT-IR), UV–Visible Spectroscopy (UV-Vis), and X-ray Diffraction (XRD). Ciprofloxacin was used as a model drug to assess the drug-loading capacity of the CS–ZnO NCs. The loading capacity and encapsulation efficiency within the CS-ZnO nanocomposite were assessed, yielding 58.5% ± 0.056 and 97.5% ± 0.056 respectively. The anti-bacterial activity was examined against Escherichia coli (Gram-negative) and Staphylococcus aureus (Gram-positive) demonstrated that cipro-loaded CS-ZnO NCs exhibited higher activity compared to individual (S. aureus : chitosan NPs (27 ± 0.02 mm), ZnO NPs (28 ± 0.01 mm), CS-ZnO NCs (27 ± 0.01 mm), and E. coli : chitosan NPs (29 ± 0.0 mm), ZnO NPs (29 ± 0.07 mm), CS-ZnO NCs (27 ± 0.08 mm)). Interestingly, the formulation showed greater activity against S. aureus (inhibition zone: 37 ± 0.01 mm) than E. coli (inhibition zone: 30 ± 0.01 mm), suggesting a combined effect among ciprofloxacin, ZnO NPs, and chitosan. Thus, this result indicates that CS-ZnO NCs could be employed as drug carrier platform for cipro, offering promising applications in anti-microbial therapy. However, drug release studies are required as part of future work to fully understand the developed system in detail.
Yeneneh et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: